Advertisement

Topics

Cambridge-based Astex Pharmaceuticals Celebrates as Cancer Drug Receives US Marketing Approval

17:17 EDT 13 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Further Milestone Payment Under Novartis Collaboration as Kisqali® (ribociclib) Receives FDA approval as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer with an aromatase inhibitor Novartis drug Ki...

Other Sources for this Article

Astex Pharmaceuticals
Jeremy Carmichael, +44(0)1223 226289
Mobile: +44 (0)7786 738066
VP Corporate Development
Head of Business Development
jeremy.carmichael@astx.com
or
Instinctif Partners
Sue Charles/ Daniel Gooch
+44 (0)20 7866 7905
astex@instinctif.com

NEXT ARTICLE

More From BioPortfolio on "Cambridge-based Astex Pharmaceuticals Celebrates as Cancer Drug Receives US Marketing Approval"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...